Micro <scp>RNA</scp> s implicated in canine diffuse large B‐cell lymphoma prognosis

Diffuse large B‐cell lymphoma (DLBCL) is the most prevalent subtype of non‐Hodgkin lymphoma (NHL) in domestic dogs, with many similarities to its human counterpart. The progression of the disease is rapid, and treatment must be initiated early to achieve cancer remission and extend life. This study examined the relationship between progression‐free survival (PFS) and microRNA (miRNA) expression in dogs with DLBCL. miRNAs are small non‐coding RNA molecules that typically regulate gene expression post‐transcriptionally. They are involved in several pathophysiological processes, including the growth and progression of cancer. Based on the analysis of small RNA sequencing (sRNA‐seq) data, we validated a group of miRNAs in lymph nodes from 44 DLBCL‐affected dogs with known outcomes. We used quantitative PCR to quantify their expression and report a specific subset of miRNAs is associated with decreased PFS in dogs with DLBCL. The miR‐192‐5p and miR‐16‐5p expression were significantly downregulated in dogs with increased PFS. These results indicate that miRNA profiling may potentially identify dogs with DLBCL that will experience poor outcomes following treatment. Identifying specific miRNAs that correlate with the progression of canine DLBCL could aid the development of individualized treatment regimens for dogs.